Literature DB >> 26721599

Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.

Lauren E Cain1, Michael S Saag2, Maya Petersen3, Margaret T May4, Suzanne M Ingle4, Roger Logan1, James M Robins1,5, Sophie Abgrall6,7, Bryan E Shepherd8, Steven G Deeks9, M John Gill10, Giota Touloumi11, Georgia Vourli11, François Dabis12, Marie-Anne Vandenhende12, Peter Reiss13,14, Ard van Sighem13, Hasina Samji15, Robert S Hogg15,16, Jan Rybniker17, Caroline A Sabin18, Sophie Jose18, Julia Del Amo19,20, Santiago Moreno21,22, Benigno Rodríguez23, Alessandro Cozzi-Lepri24, Stephen L Boswell25, Christoph Stephan26, Santiago Pérez-Hoyos27, Inma Jarrin19,20, Jodie L Guest28,29,30, Antonella D'Arminio Monforte31, Andrea Antinori32, Richard Moore33, Colin Nj Campbell20,34, Jordi Casabona20,34,35, Laurence Meyer36, Rémonie Seng36, Andrew N Phillips18, Heiner C Bucher37, Matthias Egger38,39, Michael J Mugavero40, Richard Haubrich41, Elvin H Geng42, Ashley Olson43, Joseph J Eron44, Sonia Napravnik44, Mari M Kitahata45, Stephen E Van Rompaey45, Ramón Teira46, Amy C Justice47,48, Janet P Tate47,48, Dominique Costagliola6, Jonathan Ac Sterne4, Miguel A Hernán1,5,49.   

Abstract

Background: When a clinical treatment fails or shows suboptimal results, the question of when to switch to another treatment arises. Treatment switching strategies are often dynamic because the time of switching depends on the evolution of an individual's time-varying covariates. Dynamic strategies can be directly compared in randomized trials. For example, HIV-infected individuals receiving antiretroviral therapy could be randomized to switching therapy within 90 days of HIV-1 RNA crossing above a threshold of either 400 copies/ml (tight-control strategy) or 1000 copies/ml (loose-control strategy).
Methods: We review an approach to emulate a randomized trial of dynamic switching strategies using observational data from the Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. We estimated the comparative effect of tight-control vs. loose-control strategies on death and AIDS or death via inverse-probability weighting.
Results: Of 43 803 individuals who initiated an eligible antiretroviral therapy regimen in 2002 or later, 2001 met the baseline inclusion criteria for the mortality analysis and 1641 for the AIDS or death analysis. There were 21 deaths and 33 AIDS or death events in the tight-control group, and 28 deaths and 41 AIDS or death events in the loose-control group. Compared with tight control, the adjusted hazard ratios (95% confidence interval) for loose control were 1.10 (0.73, 1.66) for death, and 1.04 (0.86, 1.27) for AIDS or death. Conclusions: Although our effective sample sizes were small and our estimates imprecise, the described methodological approach can serve as an example for future analyses.
© The Author 2015; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association

Entities:  

Keywords:  HIV; antiretroviral therapy; dynamic strategies; inverse-probability weighting; mortality; observational studies

Mesh:

Substances:

Year:  2016        PMID: 26721599      PMCID: PMC5841611          DOI: 10.1093/ije/dyv295

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   9.685


  27 in total

1.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Authors:  M A Hernán; B Brumback; J M Robins
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

Review 2.  Comparison of dynamic treatment regimes via inverse probability weighting.

Authors:  Miguel A Hernán; Emilie Lanoy; Dominique Costagliola; James M Robins
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

3.  Causal effect models for realistic individualized treatment and intention to treat rules.

Authors:  Mark J van der Laan; Maya L Petersen
Journal:  Int J Biostat       Date:  2007       Impact factor: 0.968

4.  Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.

Authors:  Hiroyu Hatano; Peter Hunt; Jodi Weidler; Eoin Coakley; Rebecca Hoh; Teri Liegler; Jeffrey N Martin; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2006-10-06       Impact factor: 9.079

5.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.

Authors:  Miguel A Hernán; Alvaro Alonso; Roger Logan; Francine Grodstein; Karin B Michels; Walter C Willett; Joann E Manson; James M Robins
Journal:  Epidemiology       Date:  2008-11       Impact factor: 4.822

7.  Constructing inverse probability weights for marginal structural models.

Authors:  Stephen R Cole; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

8.  Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification.

Authors:  Maya L Petersen; Mark J van der Laan; Sonia Napravnik; Joseph J Eron; Richard D Moore; Steven G Deeks
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

9.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1992-12-18

10.  Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems.

Authors:  Mari M Kitahata; Benigno Rodriguez; Richard Haubrich; Stephen Boswell; W Christopher Mathews; Michael M Lederman; William B Lober; Stephen E Van Rompaey; Heidi M Crane; Richard D Moore; Michael Bertram; James O Kahn; Michael S Saag
Journal:  Int J Epidemiol       Date:  2008-02-08       Impact factor: 7.196

View more
  17 in total

1.  Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.

Authors:  Ellen C Caniglia; James M Robins; Lauren E Cain; Caroline Sabin; Roger Logan; Sophie Abgrall; Michael J Mugavero; Sonia Hernández-Díaz; Laurence Meyer; Remonie Seng; Daniel R Drozd; George R Seage Iii; Fabrice Bonnet; Fabien Le Marec; Richard D Moore; Peter Reiss; Ard van Sighem; William C Mathews; Inma Jarrín; Belén Alejos; Steven G Deeks; Roberto Muga; Stephen L Boswell; Elena Ferrer; Joseph J Eron; John Gill; Antonio Pacheco; Beatriz Grinsztejn; Sonia Napravnik; Sophie Jose; Andrew Phillips; Amy Justice; Janet Tate; Heiner C Bucher; Matthias Egger; Hansjakob Furrer; Jose M Miro; Jordi Casabona; Kholoud Porter; Giota Touloumi; Heidi Crane; Dominique Costagliola; Michael Saag; Miguel A Hernán
Journal:  Stat Med       Date:  2019-03-18       Impact factor: 2.373

2.  Outcomes of HIV-positive patients with cryptococcal meningitis in the Americas.

Authors:  B Crabtree Ramírez; Y Caro Vega; B E Shepherd; C Le; M Turner; C Frola; B Grinsztejn; C Cortes; D Padgett; T R Sterling; C C McGowan; A Person
Journal:  Int J Infect Dis       Date:  2017-08-12       Impact factor: 3.623

3.  How to estimate the effect of treatment duration on survival outcomes using observational data.

Authors:  Miguel A Hernán
Journal:  BMJ       Date:  2018-02-01

4.  IVF success corrected for drop-out: use of inverse probability weighting.

Authors:  Anna M Modest; Lauren A Wise; Matthew P Fox; Jennifer Weuve; Alan S Penzias; Michele R Hacker
Journal:  Hum Reprod       Date:  2018-12-01       Impact factor: 6.918

5.  Emulating a target trial of statin use and risk of dementia using cohort data.

Authors:  Ellen C Caniglia; L Paloma Rojas-Saunero; Saima Hilal; Silvan Licher; Roger Logan; Bruno Stricker; M Arfan Ikram; Sonja A Swanson
Journal:  Neurology       Date:  2020-08-04       Impact factor: 9.910

6.  Effect of Switching Antiretroviral Treatment Regimen in Patients With Drug-Resistant HIV-1 Infection: Retrospective Observational Cohort Study.

Authors:  Yiping Li; Qinjian Wang; Shu Liang; Dan Yuan; Shujuan Yang; Chuanteng Feng; Hong Yang; Hang Yu
Journal:  JMIR Public Health Surveill       Date:  2022-06-24

7.  Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes.

Authors:  Ellen C Caniglia; Rebecca Zash; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Shahin Lockman; Jennifer Y Chen; Mompati Mmalane; Joseph Makhema; Miguel A Hernán; Roger L Shapiro
Journal:  AIDS       Date:  2018-01-02       Impact factor: 4.177

8.  Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data.

Authors:  Peter Bruun-Rasmussen; Per Kragh Andersen; Karina Banasik; Søren Brunak; Pär Ingemar Johansson
Journal:  Blood       Date:  2022-06-23       Impact factor: 25.476

9.  Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa.

Authors:  Helen Bell Gorrod; Richard Court; Michael Schomaker; Gary Maartens; Richard A Murphy
Journal:  J Acquir Immune Defic Syndr       Date:  2020-05-01       Impact factor: 3.771

10.  Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies.

Authors:  Lisanne J Dommershuijsen; Agnita J W Boon; M Kamran Ikram
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.